Nanobiotix SA banner

Wall St Price Targets

5NRA Price Targets Summary
Nanobiotix SA

Wall Street analysts forecast 5NRA stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 5NRA is 28.11 EUR with a low forecast of 19.22 EUR and a high forecast of 45.63 EUR.

Lowest Forecast
Price Target
19.22 EUR
46% Downside
Average Forecast
Price Target
28.11 EUR
21% Downside
Highest Forecast
Price Target
45.63 EUR
27% Upside
Nanobiotix SA Competitors:
Price Targets
CDNA
CareDx Inc
22% Upside
NWSA
News Corp
35% Upside
EOLS
Evolus Inc
139% Upside
NYXH
Nyxoah SA
274% Upside

Revenue
Forecast

13% / Year
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-85%
Average Miss
13% / Year
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-85%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 8 years is 72%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
10%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 5NRA's stock price target?
Price Target
28.11 EUR

According to Wall Street analysts, the average 1-year price target for 5NRA is 28.11 EUR with a low forecast of 19.22 EUR and a high forecast of 45.63 EUR.

What is the Revenue forecast for Nanobiotix SA?
Projected CAGR
72%

Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 8 years is 72%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett